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CASE REPORT
INTRODUCTION
Amyloidosis is a unique metabolic storage disease
that results from deposition of insoluble fibrillar
proteins or aberrantly folded and assembled protein
fragments in a variety of tissues, mainly in
the extracellular spaces, and not metabolized or cleared
by the body. As a conformational disease, amyloid
fibrils can be deposited locally or may involve virtually
every organ system of the body, may have no
apparent clinical consequences or may be associated
with severe pathophysiologic changes.1-3
There are distinct types of amyloidosis, which are
classified according to the protein composition of
the amyloid deposits and usually subdivided into
systemic (generalized) and localized (tissue-spesific)
forms. The clinical manifestations, prognosis, and
therapy vary greatly depending on the specific type of
amyloidosis (table 1).4 In immunoglobulin-light-chain-
related (AL) amyloidosis (also called primary
amyloidosis), an underlying monoclonal plasma-cell
disorder produces the constituents of the deposits,
which are the variable regions of the immunoglobulin
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AA amyloidosis occurs as secondary to rheumatoid arthritis, inflammatory bowel disease and other
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light chains. In AA (secondary) amyloidosis, by
contrast, the amyloidogenic precursor is a normal
acute-phase reactant called serum amyloid A (SAA),
which is produced as the result of chronic infection or
inflammation.5,6
CASE REPORT
A 57 years old female, came to hospital complained
of difficulty in swallowing that occurred since one
month before. Actually, she had already felt pain on
swallowing and difficult to eat for about 4 months
accompanied by nausea, vomiting and epigastric pain.
At first, she still could take liquid food but then it was
progressively worsening. Finally, she felt hardly
passage both liquid or solid food. She got a 20 kg
unintentional weight loss in a year. There is also
diarrhea since one month ago, with frequency of
2 - 3 defecations per day.
There is history of rheumatic disease since about
10 years, regularly control to rheumatologic division
and take methylprednisolone and ranitidine, but she had
stopped taking these drugs since one month ago.
She also had already stopped taking captopril for her
hypertension since then.
On examination, her blood pressure is
170/100 mmHg, height 155 cm and weight 35 kg. There
is lymph node enlargement in the left neck around
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2 x 2 x 2 cm and deformities on extremities, Swan  
neck and Boutonniere deformities (figure 1).  
Laboratory results showed mild anemia (11.7 g/dL),  
elevated ESR (114 mm), high GGT (103 U/L),  
hypoalbuminemia (2.6 g/dL), low transthyretin level  
(6.9 mg/dL), hypokalemia (2.7 mmol/L), no albumin- 
uria/proteinuria and no erythrocyte in urine, transferin  
level was low (51 mg/dL), TSHs and Free T4 were  
normal.  
The problem lists of the patient at admission were  
difficult intake, chronic diarrhea, rheumatoid arthritis,  
malnutrition, hypertension and lymphadenopathy colli  
sinistra. She was then proceed upper and lower 
gastrointestinal endoscopic examination. Upper 
gastrointestinal endoscopy showed hyperemia in  
the whole region of gastric mucosa (figure 2) and  
histopathologic examination of the biopsy specimen  
showed the typical deposition of amorphous,  
homogeneous and acidophilic material in the gastric  
mucosa (figure 4A & 4B) with conclusion of  
amyloidosis gaster. Lower gastrointestinal endoscopy  
showed pancolitis and ileitis, there’s appearance of  
hyperemia and erosion (figure 3) with histopathologic  
results of non-destructive chronic colitis (figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a. Swan neck and boutonniere, b. Bilateral knees arthritis 
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Figure 2. Gastric mucosal hyperemia 
Figure 3. Hyperemia and erosion of colon 
Figure 4. Gastric amyloidosis, deposition of amorphous, 
homogeneous and acidophilic material 
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Table 1. Treatment of systemic amyloidosis.4 
Type of amyloidosis 
Amyloid protein 
component Current therapy Goal of therapy 
AL or AH (primary) Immunoglobulin light chain      
(AL) or (occasionally) heavy 
chain (AH) 
Melphalan plus dexamethasone; 
alternative is autologous stem-
cell transplantation in selected 
patients with limited organ 
involvement who are candidates 
for the procedure 
 
Eradicate clonal plasma 
cells that are the source of  
immunoglobulin protein 
AA (secondary to chronic              
inflammatory or familiar 
Mediterranean fever) 
 
Serum amyloid A protein Treatment of underlying        
infection or inflammation 
colchicines  for familial        
mediterranean fever 
 
Reduce level of serum 
amyloid A protein 
Mutant ATTR (familial) Mutant form transthyretin Liver transplantation Eliminate source of mutant 
transthyretin 
 
Senile systemic amyloidosis Wild-type form of  
transthyretin 
 
No therapy  
Other forms of familial 
amyloidosis 
   
      Fibrinogen α-chain Mutant form of fibrinogen  
α-chain 
Hepatorenal transplantation Eliminate source of 
fibrinogen α-chain (liver) and 
replace  affected organ 
(kidney) 
      Lysozyme Lysozyme Undefined  
      Apolipoprotein  Apolipoproteins A-I and A-II    Renal transplantation Replace affected organ 
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DISCUSSION
Amyloidosis may be classified in different forms
characterized by the structure of deposited fibrillar
 proteinaceous amyloid. AL amyloidosis occurs in
a primary form and as a complication to myelomatosis
or Waldenstroms macroglobulinaemia. AA
amyloidosis occurs as secondary to rheumatoid arthri-
tis (like this patient), inflammatory bowel disease and
other diseases and also associated with familial
Mediterranean fever. Patients with amyloidosis may
be treated with melphalan, prednisone and colchicine.
Outcomes are worse if there are cardiac or
gastrointestinal manifestations. In AL amyloidosis
the median survival after diagnosis is 1-2 years.
In renal amyloidosis dialysis or transplantation may
improve survival.7,8
Amyloidal protein was further should be proven by
positive Congo red stain appearing red microscopically
in normal light (as shown in figure 4A & 4B) and will
exhibit green birefringence under polarized light.
Amyloid deposits could give positive reaction with
AA-antibody using peroxidase technique. A more
detailed evaluation of the amyloid composition was
beyond the capability of our laboratory.7
In 1885, the term ‘‘Congo’’ red was introduced in
Berlin at the Berlin West Africa Conference as
the name for the first direct textile dye. At the time,
European newspapers were filled with exciting stories
of the exotic Congo River basin in Central Africada
hot new geopolitical and potentially profitable area in
which to invest or exert control. Hence, the name had
marketing cache, just like another textile dye with
an African name used in medicine: Sudan black.
A patent on Congo red was issued to its inventor, Paul
Bottiger, who subsequently sold its rights to a major
German textile dyestuff company (AGFA), a firm that
ultimately merged with others to form the IG Farben
Company. A challenge to AGFA’s Congo red patent
subsequently led to a precedent-setting decision in
intellectual property law. Congo red is rarely used
today as a textile dye because it tends to change color
when handled by sweaty fingers and stains the fabrics
of other garments when washed together.
In the GI tract, amyloid may involve the
vasculature, producing changes of ischemia;
the mucosa, resulting in bleeding, malabsorption, and
diarrhea; and the muscles, causing subsequent
dysmotility and intestinal obstruction. Whitish ulcers,
black necrosis, tan polyps made largely of amyloid, and
blotches of reddish-purple may be seen. So many
colors in the rainbow!.9
The amyloid found in the gastrointestinal system
may be localized, or a part of systemic amyloidosis.
In systemic amyloidosis, gastrointestinal involvement
is common; however, local deposition of amyloid in
the gastrointestinal system without systemic
involvement is an uncommon form. As part of
systemic amyloidosis, Gilat T, suggested two patterns
of gastrointestinal amyloid deposition.10 In the AA type,
amyloid was deposited in the mucosa and the inner
layer of the blood vessels. In the AL type, amyloid
deposition was found in the muscular layer and
the outer layers of the blood vessels. Yamada et al,
confirmed these observations in their 21 autopsy cases
with amyloidosis.11
Localized gastric amyloidosis is characterized by
mucosal or submucosal amyloid deposition in
the gastric wall. Subclinical gastrointestinal involvement
in amyloidosis is common, occurring in up to 98% of
patients. The clinical manifestations of the gastro-
intestinal amyloidosis were often uncharacteristic, and
it is difficult to assess the incidence of clinical
symptoms, which are said to occur in less than 20% of
cases. The clinical manifestations are varied, including
motility disorders, bleeding, malabsorption, obstruction,
protein-losing enteropathy and perforation. As for
localized gastric amyloidosis, a variety of common
gastrointestinal symptoms such as epigastric
discomfort, poor appetite, hematemesis, hematochezia
and gastric perforation may occur in the process of
this disease. Gastric amyloidosis shows association with
gastric malignancies, such as carcinoma and stromal
tumor. Hematologic malignancies including plasma cell
dyscrasia and gastrointestinal lymphoma have
occasionally been reported in association with
amyloidosis.6,7
Amyloid-associated gastrointestinal dismotility can
be manifested as intestinal pseudoobstruction, diarrhea,
or achalasia. GI symptoms typically include anorexia,
eating difficulty due to macroglossia, and altered bowel
habits. Nausea may occur in up to 40% of patients
with amyloidosis. Clinical gastroparesis occurs rarely
in patients with amyloidosis; one study reported only
3 cases in 769 patients.12,13 In this patient,
the predominant symptoms are nausea, vomiting,
epigastric pain, odynophagia and dysphagia.
The possibility of amyloidosis may cause chronic
diarrhea in this patient remain to be established,
further histopathologic evaluation with the Congo red
stain should be done to get certainty.
We have presented herein a case of gastric
amyloidosis that was found associated with
Figure 5. Chronic colitis
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rheumatoid arthritis. It showed morphological features
identical to those previously described as a systemic
amyloidosis and manifested as dyspepsia and difficult
intake.
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